Literature DB >> 9529093

A recombinant live attenuated strain of Vibrio cholerae induces immunity against tetanus toxin and Bordetella pertussis tracheal colonization factor.

I Chen1, T M Finn, L Yanqing, Q Guoming, R Rappuoli, M Pizza.   

Abstract

An attenuated strain of Vibrio cholerae was used as a carrier for the expression of heterologous antigens such as fragment C from tetanus toxin (TetC) and tracheal colonization factor from Bordetella pertussis (Tcf). In vitro, high levels of protein were obtained when the Escherichia coli nirB promoter was used and the bacteria were grown with low aeration. Intranasal immunization of mice with IEM101 expressing TetC elicited serum vibriocidal activity and induced antibodies against tetanus toxin which were protective against lethal challenge with 10 times the 50% lethal dose of tetanus toxin. Bacterial viability was essential for the induction of anti-TetC antibodies. Intranasal administration of IEM101 expressing Tcf induced a significant reduction in bacterial colonization of the tracheas of mice challenged with wild-type B. pertussis. These data are in agreement with the putative role of Tcf in Bordetella tracheal colonization. In conclusion, we have demonstrated that V. cholerae may be used as a live vector to deliver heterologous antigens in vivo and that protection to both systemic and local challenge may be achieved.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9529093      PMCID: PMC108100     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  Development of a germfree mouse model of Vibrio cholerae infection.

Authors:  J R Butterton; E T Ryan; R A Shahin; S B Calderwood
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

2.  Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908.

Authors:  E M Barry; O Gomez-Duarte; S Chatfield; R Rappuoli; M Pizza; G Losonsky; J Galen; M M Levine
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

3.  A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens.

Authors:  J E Galen; O G Gomez-Duarte; G A Losonsky; J L Halpern; C S Lauderbaugh; S Kaintuck; M K Reymann; M M Levine
Journal:  Vaccine       Date:  1997 Apr-May       Impact factor: 3.641

4.  Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin.

Authors:  G Douce; M Fontana; M Pizza; R Rappuoli; G Dougan
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

5.  Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains.

Authors:  J R Butterton; E T Ryan; D W Acheson; S B Calderwood
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

6.  A natural vaccine candidate strain against cholera.

Authors:  Y Q Liu; G M Qi; S X Wang; Y M Yu; G C Duan; L J Zhang; S Y Gao
Journal:  Biomed Environ Sci       Date:  1995-12       Impact factor: 3.118

7.  Use of recombinase gene fusions to identify Vibrio cholerae genes induced during infection.

Authors:  A Camilli; J J Mekalanos
Journal:  Mol Microbiol       Date:  1995-11       Impact factor: 3.501

8.  Development of Shigella sonnei live oral vaccines based on defined rfbInaba deletion mutants of Vibrio cholerae expressing the Shigella serotype D O polysaccharide.

Authors:  D Favre; S J Cryz; J F Viret
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

9.  Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection.

Authors:  D H Jones; B W McBride; C Thornton; D T O'Hagan; A Robinson; G H Farrar
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

10.  A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity.

Authors:  S Yamamoto; H Kiyono; M Yamamoto; K Imaoka; K Fujihashi; F W Van Ginkel; M Noda; Y Takeda; J R McGhee
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

View more
  10 in total

1.  Construction and characterization of a thyA mutant derived from cholera vaccine candidate IEM101.

Authors:  Fenggang Yu; Guoming Qi; Yanqing Liu; Shouyi Gao; Biao Kan
Journal:  Mol Biotechnol       Date:  2005-03       Impact factor: 2.695

2.  Cell surface-exposed tetanus toxin fragment C produced by recombinant Bacillus anthracis protects against tetanus toxin.

Authors:  S Mesnage; M Weber-Levy; M Haustant; M Mock; A Fouet
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Protective antigen-mediated antibody response against a heterologous protein produced in vivo by Bacillus anthracis.

Authors:  F Brossier; M Weber-Levy; M Mock; J C Sirard
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 4.  Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.

Authors:  Dorji Dorji; Frits Mooi; Osvaldo Yantorno; Rajendar Deora; Ross M Graham; Trilochan K Mukkur
Journal:  Med Microbiol Immunol       Date:  2017-11-21       Impact factor: 3.402

5.  Comparison of a regulated delayed antigen synthesis system with in vivo-inducible promoters for antigen delivery by live attenuated Salmonella vaccines.

Authors:  Shifeng Wang; Yuhua Li; Huoying Shi; Wei Sun; Kenneth L Roland; Roy Curtiss
Journal:  Infect Immun       Date:  2010-12-06       Impact factor: 3.441

Review 6.  Exploiting cholera vaccines as a versatile antigen delivery platform.

Authors:  Anisia J Silva; Francis O Eko; Jorge A Benitez
Journal:  Biotechnol Lett       Date:  2007-11-16       Impact factor: 2.461

7.  Use of stabilized luciferase-expressing plasmids to examine in vivo-induced promoters in the Vibrio cholerae vaccine strain CVD 103-HgR.

Authors:  Cara E Morin; James B Kaper
Journal:  FEMS Immunol Med Microbiol       Date:  2009-07-01

8.  In vivo expression and immunoadjuvancy of a mutant of heat-labile enterotoxin of Escherichia coli in vaccine and vector strains of Vibrio cholerae.

Authors:  E T Ryan; T I Crean; M John; J R Butterton; J D Clements; S B Calderwood
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

9.  Effect of vaccination on Bordetella pertussis strains, China.

Authors:  Liu Zhang; Yinghua Xu; Jianhong Zhao; Teemu Kallonen; Shenghui Cui; Yunqiang Xu; Qiming Hou; Fengxiang Li; Junzhi Wang; Qiushui He; Shumin Zhang
Journal:  Emerg Infect Dis       Date:  2010-11       Impact factor: 6.883

10.  Mucosal Immunization Against Pertussis: Lessons From the Past and Perspectives.

Authors:  Violaine Dubois; Camille Locht
Journal:  Front Immunol       Date:  2021-06-15       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.